

Patients Against Lymphoma



3774 Buckwampum Road, Riegelsville PA 18077
Tel: 610-346-8419 | Fax: 801-409-5736 | Email: KarlS@Lymphomation.org

February 21, 2008

Mr. Herb Kuhn, Deputy Director
Centers for Medicare and Medicaid Services
Hubert H. Humphrey Building
200 Independence Avenue S. W.
Washington, D.C. 20201

Re: CMS-1392-FC - reimbursement rates for radioimmunotherapy (RIT) treatments
BEXXAR® Therapeutic Regimen (Tositumomab + Iodine 131 Tositumomab) and
ZEVALIN® Therapeutic Regimen (Ibritumomab Tiuxetan)

Dear Mr. Kuhn:

Thank you for the opportunity to meet with you. We represent lymphoma patients and their families who are very concerned that payment rates set forth in the Final Rule will severely limit, or even deny, patient access to Bexxar and Zevalin and threaten the future of related therapeutic innovations. We are thus seeking your assurance that payment rates for this new class of therapy will ensure continued patient access while CMS also works to meet its requirements.

We propose the following agenda for discussion:

- The implication of the Final Rule for patients
- Appropriate reimbursements, cost effectiveness and claims data
- The concept of inseparable components of RIT, all geared to therapy
- Implication for future similar therapies

Because these are complex issues that cannot be discussed in detail in a short time, we are also attaching materials about these topics for your review prior to our meeting.

We and the patients we represent are depending on you and the leadership of CMS to make sure that Bexxar and Zevalin remain available now and after June 30, 2008, and we deeply appreciate your listening to our concerns.

Sincerely,

A handwritten signature in black ink, appearing to read "Karl Schwartz".

Karl Schwartz

A handwritten signature in black ink, appearing to read "Betsy de Parry".

Betsy de Parry

Att.

MEETING PARTICIPANTS

Karl Schwartz, B.A., M.F.A.
3774 Buckwampum Road
Riegelsville, Pennsylvania 18077
Phone: (610) 346-8419
Email: KarlS@lymphomation.org

- President and Co-Founder, Patients Against Lymphoma
- Patient Consultant to the FDA/Oncologic Drugs Advisory Committee (ODAC)
- Participant: NCA Progress Review Group for Blood Cancers (LMPRG)
- Participant: Biospecimen Access and Ethical, Legal and Policy Issues Workshop (ELP)
- Participant: Custodianship and Ownership Issues in Biospecimen Research Symposium

Betsy de Parry
6310 Sandy Creek Court
Ann Arbor, Michigan 48103
Phone: (734) 216-5872
Email: betsy@annarborbuilders.com

- Advocacy Advisor, Patients Against Lymphoma
- Lymphoma Survivor

Mark S. Kaminski, M.D.
Professor of Internal Medicine
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan
1500 E. Medical Center Drive
Ann Arbor, Michigan
Phone: (734) 936-5310

- Director, Multidisciplinary Lymphoma Clinic, University of Michigan Medical Center and Cancer Center, Ann Arbor, Michigan
- Co-Director, Leukemia/Lymphoma & BMT Program, University of Michigan Cancer Center, Ann Arbor, Michigan